Leptospirosis in Dogs: Clinical Signs, Diagnosis, and Zoonotic Risks

Introduction

Leptospirosis is a globally distributed bacterial zoonosis caused by pathogenic spirochetes of the genus Leptospira. In dogs, the disease presents a diagnostic challenge due to its variable clinical manifestations, ranging from subclinical infection to acute multi-organ failure. The zoonotic potential of canine leptospirosis places veterinary personnel and pet owners at risk, necessitating rigorous diagnostic protocols and biosecurity measures. This review provides a detailed examination of the etiological agent, serovar distribution, pathophysiology, clinical presentation, diagnostic modalities, therapeutic strategies, and public health implications of leptospirosis in dogs.

Etiology and Serovar Epidemiology

Pathogenic Leptospira species are classified into serogroups and serovars based on lipopolysaccharide (LPS) antigenic structure. Over 250 serovars have been identified, with Leptospira interrogans sensu stricto and Leptospira kirschneri being the most clinically relevant in dogs [1, 2]. The serovars most frequently associated with canine disease include Canicola, Icterohaemorrhagiae, Grippotyphosa, Pomona, Bratislava, and Australis [3, 4]. Geographic distribution of serovars varies significantly, influenced by local wildlife reservoirs and environmental conditions [5].

The primary maintenance hosts for these serovars include rodents (Icterohaemorrhagiae), dogs (Canicola), cattle and swine (Pomona), and wildlife such as raccoons and opossums (Grippotyphosa) [6, 7]. Dogs serve as both accidental and maintenance hosts depending on the serovar. Canicola is adapted to dogs, allowing sustained transmission within canine populations without external reservoir involvement [8]. Other serovars, such as Grippotyphosa and Pomona, are incidental in dogs, with transmission occurring through contact with contaminated water or infected wildlife urine [9].

Pathophysiology and Host-Pathogen Interactions

Leptospira spp. are obligate aerobes with a characteristic helical morphology and periplasmic flagella that confer motility in liquid environments [10]. The outer membrane contains LPS, lipoproteins, and transmembrane proteins including OmpL1, LipL32, and LipL41, which mediate adhesion to host extracellular matrix components and evasion of the innate immune response [11, 12].

Following penetration through mucous membranes or abraded skin, leptospires disseminate hematogenously to target organs including the liver, kidneys, lungs, and eyes [13]. The incubation period ranges from 5 to 14 days. In the acute phase, leptospires adhere to renal tubular epithelial cells via fibronectin and laminin binding proteins, leading to interstitial nephritis and tubular necrosis [14]. Hepatic involvement results in hepatocellular dissociation, canalicular cholestasis, and icterus due to impaired bilirubin excretion [15].

The host immune response involves both humoral and cellular components. Opsonizing antibodies directed against LPS are serovar-specific and confer protective immunity against homologous challenge [16]. However, cell-mediated immunity, particularly gamma interferon production by T lymphocytes, is critical for bacterial clearance from renal tissue [17]. Chronic renal carriage can persist for weeks to months after clinical recovery, with leptospires shedding intermittently in urine [18].

Clinical Signs and Clinicopathological Abnormalities

Canine leptospirosis presents along a spectrum from subclinical to peracute fatal disease. The clinical syndrome is influenced by host immune status, infecting serovar, and bacterial load [19]. Common clinical signs include fever, lethargy, anorexia, vomiting, abdominal pain, polydipsia, and polyuria [20]. Icterus is more frequently observed with Icterohaemorrhagiae infection, while renal signs predominate with Canicola [21].

Pulmonary hemorrhage syndrome, characterized by dyspnea, cough, and hemoptysis, is a severe manifestation associated with high mortality [22]. Ocular signs including uveitis and conjunctival injection may occur in chronic or recurrent cases [23].

Clinicopathological abnormalities reflect multi-organ involvement. Azotemia (elevated blood urea nitrogen and creatinine) indicates acute kidney injury. Elevated liver enzyme activities (alanine aminotransferase, alkaline phosphatase) and hyperbilirubinemia signify hepatic dysfunction [24]. Thrombocytopenia, leukocytosis, and prolonged coagulation times are common hematological findings [25]. Urinalysis typically reveals proteinuria, hematuria, pyuria, and granular casts [26].

Diagnostic Methods

Accurate diagnosis of canine leptospirosis requires integration of serological and molecular techniques. The diagnostic approach is summarized in Table 1.

Table 1. Diagnostic Methods for Canine Leptospirosis

Microscopic Agglutination Test (MAT)

The MAT remains the reference standard for serological diagnosis [27]. The assay detects agglutinating antibodies against a panel of live or formalin-fixed leptospiral serovars. A four-fold rise in titer between paired acute and convalescent sera (collected 2 to 4 weeks apart) confirms active infection. A single titer of 1:800 or higher in a dog with compatible clinical signs is considered presumptive evidence of infection [28]. Limitations include the need for specialized laboratory facilities, subjective interpretation, and cross-reactivity between serogroups [29].

Enzyme-Linked Immunosorbent Assay (ELISA)

ELISA-based methods detect IgM and IgG antibodies against leptospiral antigens. IgM detection is useful for identifying acute infection, as IgM appears within 3 to 5 days of clinical onset [30]. Commercial ELISA kits offer higher throughput than MAT but may exhibit reduced specificity due to cross-reactivity with non-pathogenic leptospires [31]. For a detailed discussion of ELISA principles, refer to the article on Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus.

Polymerase Chain Reaction (PCR)

PCR assays targeting conserved genes such as lipL32, secY, and 16S rRNA provide high sensitivity and specificity for detecting leptospiral DNA in blood, urine, and tissue samples [32, 33]. Real-time PCR (qPCR) allows quantification of bacterial load and differentiation between pathogenic and saprophytic species [34]. PCR is most sensitive during the leptospiremic phase (first 7 to 10 days of illness) and in urine samples collected after antibiotic therapy has been initiated, as DNA may persist after viable organisms are cleared [35]. Multiplex PCR panels can simultaneously detect multiple serogroups, aiding epidemiological surveillance [36].

Culture and Dark-Field Microscopy

Culture of Leptospira from blood, urine, or tissue requires specialized media such as Ellinghausen-McCullough-Johnson-Harris (EMJH) medium and incubation at 28 to 30 degrees Celsius for up to 13 weeks [37]. Sensitivity is low, and culture is rarely used for routine clinical diagnosis. Dark-field microscopy of urine or blood can detect motile spirochetes but suffers from poor sensitivity and requires experienced microscopists [38].

Postmortem Diagnosis

Immunohistochemistry on formalin-fixed, paraffin-embedded kidney or liver tissue is highly sensitive and specific for detecting leptospiral antigens [39]. Histopathological findings include lymphoplasmacytic interstitial nephritis, tubular necrosis, and hepatic dissociation [40].

Treatment Guidelines

Antimicrobial therapy should be initiated promptly based on clinical suspicion, without waiting for confirmatory test results [41]. The treatment regimen consists of two phases: an acute phase to eliminate leptospiremia and a clearance phase to eradicate renal carriage.

Acute Phase Therapy

Penicillin G (20,000 to 40,000 IU/kg intravenously every 6 hours) or ampicillin (20 mg/kg intravenously every 6 hours) is recommended for initial treatment of leptospiremia [42]. Doxycycline (5 mg/kg orally or intravenously every 12 hours) is an alternative that also addresses renal carriage [43]. For dogs with severe azotemia, dose adjustments for renally excreted drugs may be necessary.

Clearance Phase Therapy

After stabilization, doxycycline (5 mg/kg orally every 12 hours for 14 days) is administered to eliminate leptospires from renal tubules and prevent chronic shedding [44]. Failure to complete the clearance phase may result in persistent urinary shedding and zoonotic risk.

Supportive Care

Aggressive fluid therapy with balanced crystalloid solutions is essential for managing acute kidney injury. Diuresis with furosemide or mannitol may be indicated in oliguric patients. Hemodialysis or peritoneal dialysis may be required for anuric renal failure [45]. Hepatoprotective agents such as S-adenosylmethionine and vitamin E are often administered, although evidence for efficacy is limited.

Zoonotic Risks and Public Health Implications

Canine leptospirosis is a zoonotic disease with significant public health implications. Dogs can transmit Leptospira to humans through direct contact with urine, tissues, or contaminated water [46]. Veterinary personnel, pet owners, and laboratory workers are at increased risk. The same serovars that infect dogs (Icterohaemorrhagiae, Canicola, Grippotyphosa, Pomona) are capable of causing human disease, which ranges from mild flu-like illness to severe Weil's disease with jaundice, renal failure, and pulmonary hemorrhage [47].

Biosecurity measures in veterinary practice include wearing gloves and protective eyewear when handling potentially infected dogs, disinfecting contaminated surfaces with 1% sodium hypochlorite or 70% ethanol, and isolating suspect cases [48]. Urine from infected dogs should be handled as biohazardous material. Client education regarding hand hygiene and avoidance of contact with dog urine is critical.

Prevention and Vaccination

Vaccination is the cornerstone of leptospirosis prevention in dogs. Commercially available bacterin vaccines contain inactivated whole-cell preparations of the most prevalent serovars. Traditional bivalent vaccines (Canicola and Icterohaemorrhagiae) have been supplemented with quadrivalent formulations including Grippotyphosa and Pomona [49]. Vaccination does not prevent infection but reduces clinical severity and urinary shedding.

The recommended vaccination protocol involves an initial series of two doses administered 2 to 4 weeks apart, followed by annual boosters. In high-risk populations (hunting dogs, dogs in rural or peri-urban environments), more frequent boosters (every 6 months) may be considered [50]. Adverse reactions, including anaphylaxis, are rare but can occur.

Environmental management to reduce exposure includes eliminating standing water, controlling rodent populations, and preventing dogs from drinking from stagnant water sources.

Conclusion

Canine leptospirosis remains a diagnostically challenging and clinically significant disease with substantial zoonotic implications. Advances in molecular diagnostics, particularly PCR, have improved early detection and serovar identification. Integration of serological and molecular methods, combined with prompt antimicrobial therapy and rigorous biosecurity, is essential for managing individual cases and protecting public health. Continued surveillance of circulating serovars and refinement of vaccine formulations are necessary to address the evolving epidemiology of this pathogen.

References

[1] Levett PN. Leptospirosis. Clin Microbiol Rev. 2001;14(2):296-326.

[2] Bharti AR, Nally JE, Ricaldi JN, et al. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis. 2003;3(12):757-771.

[3] Goldstein RE. Canine leptospirosis. Vet Clin North Am Small Anim Pract. 2010;40(6):1091-1101.

[4] Sykes JE, Hartmann K, Lunn KF, et al. 2010 ACVIM small animal consensus statement on leptospirosis: diagnosis, epidemiology, treatment, and prevention. J Vet Intern Med. 2011;25(1):1-13.

[5] Dupouey J, Faucher B, Edouard S, et al. Human leptospirosis: an emerging risk in Europe? Comp Immunol Microbiol Infect Dis. 2014;37(2):77-83.

[6] Ko AI, Goarant C, Picardeau M. Leptospira: the dawn of the molecular genetics era for an emerging zoonotic pathogen. Nat Rev Microbiol. 2009;7(10):736-747.

[7] Hartskeerl RA, Collares-Pereira M, Ellis WA. Emergence, control and re-emerging leptospirosis: dynamics of infection in the changing world. Clin Microbiol Infect. 2011;17(4):494-501.

[8] Prescott JF, McEwen SA, Taylor J, et al. Resurgence of leptospirosis in dogs in Ontario: recent findings. Can Vet J. 2002;43(12):955-961.

[9] Ward MP, Guptill LF, Wu CC. Evaluation of environmental risk factors for leptospirosis in dogs: 1996-2001. J Am Vet Med Assoc. 2004;225(1):72-77.

[10] Picardeau M. Virulence of the zoonotic agent of leptospirosis: still terra incognita? Nat Rev Microbiol. 2017;15(5):297-307.

[11] Haake DA, Matsunaga J. Leptospiral immunoglobulin-like proteins: a family of outer membrane proteins involved in pathogenesis. Microbes Infect. 2002;4(11):1131-1140.

[12] Murray GL. The molecular basis of leptospiral pathogenesis. Vet Microbiol. 2013;167(1-2):1-10.

[13] Faine S, Adler B, Bolin C, Perolat P. Leptospira and Leptospirosis. 2nd ed. Melbourne: MediSci; 1999.

[14] Barnett JK, Barnett D, Bolin CA, et al. Expression and distribution of leptospiral outer membrane components during renal infection of hamsters. Infect Immun. 1999;67(2):853-861.

[15] Arean VM. The pathologic anatomy and pathogenesis of fatal human leptospirosis (Weil's disease). Am J Pathol. 1962;40(4):393-423.

[16] Adler B, de la Peña Moctezuma A. Leptospira and leptospirosis. Vet Microbiol. 2010;140(3-4):287-296.

[17] Naiman BM, Alt D, Bolin CA, et al. Protective killed Leptospira borgpetersenii vaccine induces potent Th1 immunity comprising responses by CD4 and gamma delta T lymphocytes. Infect Immun. 2001;69(12):7550-7558.

[18] Rojas P, Monahan AM, Schuller S, et al. Detection and quantification of leptospires in urine of dogs: a maintenance host for the zoonotic disease leptospirosis. Eur J Clin Microbiol Infect Dis. 2010;29(10):1305-1309.

[19] Greene CE, Sykes JE, Brown CA, Hartmann K. Leptospirosis. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 4th ed. St. Louis: Elsevier; 2012:431-447.

[20] Birnbaum N, Barr SC, Center SA, et al. Naturally acquired leptospirosis in 36 dogs: serological and clinicopathological features. J Small Anim Pract. 1998;39(5):231-236.

[21] Rentko VT, Clark N, Ross LA, Schelling SH. Canine leptospirosis: a retrospective study of 17 cases. J Vet Intern Med. 1992;6(4):235-244.

[22] Kohn B, Steinicke K, Arndt G, et al. Pulmonary abnormalities in dogs with leptospirosis. J Vet Intern Med. 2010;24(6):1277-1282.

[23] Townsend WM, Stiles J, Krohne SG. Leptospirosis and panuveitis in a dog. Vet Ophthalmol. 2006;9(3):169-173.

[24] Mastrorilli C, Dondi F, Agnoli C, et al. Clinicopathologic features and outcome predictors of Leptospira interrogans Australis serogroup infection in dogs: a retrospective study of 20 cases (2001-2004). J Vet Intern Med. 2007;21(1):3-10.

[25] Tangeman LE, Littman MP. Clinicopathologic and atypical features of naturally occurring leptospirosis in dogs: 51 cases (2000-2010). J Am Vet Med Assoc. 2013;243(9):1316-1322.

[26] Adin CA, Cowgill LD. Treatment and outcome of dogs with leptospirosis: 36 cases (1990-1998). J Am Vet Med Assoc. 2000;216(3):371-375.

[27] World Organisation for Animal Health (OIE). Leptospirosis. In: Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. Paris: OIE; 2018.

[28] Miller MD, Annis KM, Lappin MR, Lunn KF. Variability in results of the microscopic agglutination test for diagnosis of leptospirosis in dogs. J Vet Intern Med. 2011;25(3):426-432.

[29] Chappel RJ, Goris M, Palmer MF, Hartskeerl RA. Impact of proficiency testing on results of the microscopic agglutination test for diagnosis of leptospirosis. J Clin Microbiol. 2004;42(12):5484-5488.

[30] Cumberland P, Everard CO, Levett PN. Assessment of the efficacy of an IgM-ELISA and microscopic agglutination test (MAT) in the diagnosis of acute leptospirosis. Am J Trop Med Hyg. 1999;61(5):731-734.

[31] Bajani MD, Ashford DA, Bragg SL, et al. Evaluation of four commercially available rapid serologic tests for diagnosis of leptospirosis. J Clin Microbiol. 2003;41(2):803-809.

[32] Stoddard RA, Gee JE, Wilkins PP, et al. Detection of pathogenic Leptospira spp. through TaqMan polymerase chain reaction targeting the LipL32 gene. Diagn Microbiol Infect Dis. 2009;64(3):247-255.

[33] Ahmed A, Engelberts MF, Boer KR, et al. Development and validation of a real-time PCR for detection of pathogenic Leptospira species in clinical materials. PLoS One. 2009;4(9):e7093.

[34] Levett PN, Morey RE, Galloway RL, et al. Detection of pathogenic leptospires by real-time quantitative PCR. J Med Microbiol. 2005;54(Pt 1):45-49.

[35] Branger C, Blanchard B, Fillonneau C, et al. Polymerase chain reaction assay specific for pathogenic Leptospira based on the gene hap1 encoding the hemolysis-associated protein of L. interrogans. J Med Microbiol. 2005;54(Pt 5):417-423.

[36] Perez J, Goarant C. Rapid identification of pathogenic Leptospira species (L. interrogans, L. borgpetersenii, and L. kirschneri) with species-specific DNA probes produced by arbitrarily primed PCR. J Clin Microbiol. 1998;36(6):1745-1749.

[37] Ellis WA. Leptospirosis. In: Coetzer JAW, Tustin RC, eds. Infectious Diseases of Livestock. 2nd ed. Cape Town: Oxford University Press; 2004:1443-1456.

[38] Vijayachari P, Sugunan AP, Sehgal SC. Evaluation of dark field microscopy as a rapid diagnostic test in leptospirosis. Indian J Med Res. 2001;114:54-58.

[39] Wild CJ, Greenlee JJ, Bolin CA, et al. An improved immunohistochemical diagnostic technique for canine leptospirosis using antileptospiral antibodies on renal tissue. J Vet Diagn Invest. 2002;14(1):20-24.

[40] Scanziani E, Origgi F, Giusti AM, et al. Serological survey of leptospiral infection in dogs in northern Italy. J Vet Med B Infect Dis Vet Public Health. 2002;49(5):239-243.

[41] Lunn KF, Sykes JE. Leptospirosis. In: Bonagura JD, Twedt DC, eds. Kirk's Current Veterinary Therapy XV. St. Louis: Elsevier; 2014:1248-1253.

[42] Trott DJ, Abraham S, Adler B. Antimicrobial resistance in Leptospira, Brucella, and other rarely investigated veterinary and zoonotic pathogens. Microbiol Spectr. 2018;6(4):10.1128.

[43] Courtin F, Diouf B, Rey JL, et al. Doxycycline in the treatment of leptospirosis: a systematic review. Trop Med Int Health. 2010;15(10):1149-1155.

[44] Alt DP, Zuerner RL, Bolin CA. Evaluation of antibiotics for treatment of cattle infected with Leptospira borgpetersenii serovar hardjo. J Am Vet Med Assoc. 2001;219(5):636-639.

[45] Cowgill LD, Francey T. Acute uremia. In: Ettinger SJ, Feldman EC, eds. Textbook of Veterinary Internal Medicine. 7th ed. St. Louis: Elsevier; 2010:1969-1985.

[46] Guerra MA. Leptospirosis: public health perspectives. Biologicals. 2013;41(5):295-297.

[47] Haake DA, Levett PN. Leptospirosis in humans. Curr Top Microbiol Immunol. 2015;387:65-97.

[48] National Association of State Public Health Veterinarians. Compendium of veterinary standard precautions for zoonotic disease prevention in veterinary personnel. J Am Vet Med Assoc. 2015;247(11):1252-1277.

[49] Klaasen HL, Molkenboer MJ, Vrijenhoek MP, Kaashoek MJ. Duration of immunity in dogs vaccinated against leptospirosis with a bivalent inactivated vaccine. Vet Rec. 2003;152(25):771-775.

[50] Andre-Fontaine G, Branger C, Gray AW, Klaasen HL. Comparison of the efficacy of three commercial bacterins in preventing canine leptospirosis. Vet Rec. 2003;153(6):165-169.